Cochlear implants (CI) are the treatment of choice in profoundly deaf patients. Measuring the electrically evoked compound action potential (ECAP) has become an important tool for verifying the function of the spiral ganglion neurons (SGN), which are the target cells of the CI stimulation. ECAP measurement is only possible after electrode insertion. No information about the neuronal health status is available before cochlear implantation. We investigated possible correlations between the ECAP amplitude growth function (AGF) slope and anamnestic parameters to identify possible predictors for SGN health status and therefore for CI outcome. The study included patients being implanted with various electrode array lengths. Correlation analysis was performed for the mean AGF slope of the whole array, for separate electrodes as well as for grouped electrodes of the apical, medial, and basal region, with duration of deafness, age at implantation, residual hearing (grouped for electrode length), and etiology. The mean ECAP AGF slopes decreased from apical to basal. They were not correlated to the length of the electrode array or any etiology. For the mean of the full array or when grouped for the apical, middle, and basal part, the ECAP AGF slope was negatively correlated to the duration of hearing loss and the age at implantation. Since a significant negative correlation of the ECAP AGF slope and age at cochlear implantation and duration of deafness was observed, this study supports the statement that early implantation of a CI is recommended for sensorineural hearing loss. Additional factors such as the cochlear coverage and insertion angle influence the ECAP AGF slope and performance of the patient and should be included in future multifactorial analysis to study predictive parameters for the CI outcome.
Cochlear implants (CI) are the treatment of choice in profoundly deaf pan class="Species">patients. Measuring the electrically evoked compn>ound action potential (ECAn>an class="Chemical">P) has become an important tool for verifying the function of the spiral ganglion neurons (SGN), which are the target cells of the CI stimulation. ECAP measurement is only possible after electrode insertion. No information about the neuronal health status is available before cochlear implantation. We investigated possible correlations between the ECAP amplitude growth function (AGF) slope and anamnestic parameters to identify possible predictors for SGN health status and therefore for CI outcome. The study included patients being implanted with various electrode array lengths. Correlation analysis was performed for the mean AGF slope of the whole array, for separate electrodes as well as for grouped electrodes of the apical, medial, and basal region, with duration of deafness, age at implantation, residual hearing (grouped for electrode length), and etiology. The mean ECAPAGF slopes decreased from apical to basal. They were not correlated to the length of the electrode array or any etiology. For the mean of the full array or when grouped for the apical, middle, and basal part, the ECAPAGF slope was negatively correlated to the duration of hearing loss and the age at implantation. Since a significant negative correlation of the ECAPAGF slope and age at cochlear implantation and duration of deafness was observed, this study supports the statement that early implantation of a CI is recommended for sensorineural hearing loss. Additional factors such as the cochlear coverage and insertion angle influence the ECAPAGF slope and performance of the patient and should be included in future multifactorial analysis to study predictive parameters for the CI outcome.
Authors: A Eliot Shearer; Robert W Eppsteiner; Kathy Frees; Viral Tejani; Christina M Sloan-Heggen; Carolyn Brown; Paul Abbas; Camille Dunn; Marlan R Hansen; Bruce J Gantz; Richard J H Smith Journal: Hear Res Date: 2017-02-15 Impact factor: 3.208
Authors: Seiji B Shibata; Sarah R Cortez; Lisa A Beyer; James A Wiler; Adriana Di Polo; Bryan E Pfingst; Yehoash Raphael Journal: Exp Neurol Date: 2010-01-28 Impact factor: 5.330
Authors: Verena Scheper; Melanie Schmidtheisler; Florian Lasch; Heiko von der Leyen; Armin Koch; Jana Schwieger; Andreas Büchner; Anke Lesinski-Schiedat; Thomas Lenarz Journal: Trials Date: 2020-07-14 Impact factor: 2.279
Authors: Lutz Gärtner; Philipp Spitzer; Kathrin Lauss; Marko Takanen; Thomas Lenarz; Sebastian Hoth Journal: PLoS One Date: 2021-11-01 Impact factor: 3.240